Transparency Market Research (TMR) has published a new report titled, ‘Antithrombin Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’. According to the report, the global antithrombin treatment market was valued at US$ 0.50 Bn in 2018 and is projected to expand at a CAGR of 5.3% from 2019 to 2027. Overview
Antithrombotic drugs help in the prevention or inhibition of thrombus by mimicking the role of antithrombin, a protein molecule produced in the body, which helps in clotting. Antithrombin is a small protein involved in the inactivation of several enzymes in the coagulation system. It is used in several medical treatments such as hereditary antithrombin deficiency, ECMO, DIC, and sepsis. Engineered recombinant antithrombin has gained clinical significance in recent years for the prevention of various peripartum and perioperative thromboembolic events or blood clots. The antithrombin treatment market is currently a booming one, due to rise in awareness and acceptance of antithrombin therapy in proven applications and adoption of medical conditions such as hereditary antithrombin deficiency, and prevention of various peripartum and perioperative thromboembolic events or blood clots, ECMO, DIC, and sepsis. Moreover, increasing use in combination therapy of antithrombin with heparin is likely to further support the growth of the market.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=4500
North America dominate the global antithrombin treatment market in 2018 and the trend is anticipated to continue during the forecast period. Early adoption of advaced therapies and well established healthcare infrastructure accentuate antithrombin treatment market growth in the region. Asia Pacific is likely to be a highly lucrative market for the antithrombin treatment market and it is expected to expand at a high CAGR during the forecast period. Rise in demand of therapeutic antithrombin, low pricing pressure, increasing healthcare expenditure are key factors likely to boost antithrombin treatment market in Asia Pacific.
Exploring Use of Antithrombin Products to Drive Global Antithrombin Treatment Market
Antithrombotic drugs act by imitating antithrombin protein, molecule which is produced by liver and is involved in clotting and thus support in the prevention or inhibition of thrombus. Antithrombin protein molecule is synthesized by the liver, and along with other benefits, it has coagulant effects. Engineered recombinant antithrombin has gained clinical significant in recent years for the prevention of various peri-partum and peri-operative thromboembolic events or blood clots. Discovering new indications over the existing ones will create gigantic opportunity with rising demand during the forecast period. For instance. In Feb 2014, rEVO Biologics Inc. submitted IND application for ATryn for the treatment of preeclampsia with the USFDA Exploring new applications of antithrombin products drive the growth of global antithrombin market.